12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NT-300: Phase III started

Romark began a double-blind, placebo-controlled, international Phase III trial to compare twice-daily 600 mg NT-300 alone or in combination with twice-daily 75 mg oral Tamiflu oseltamivir for 5 days vs. Tamiflu alone...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >